* Alfacell Corp., of Bloomfield, N.J., raised $4.2 millionin a private placement of nearly 2 million shares toinstitutional and individual investors. The stock sale alsoincluded warrants to purchase another 96,000 Alfacellshares.
* Applied Technology Genetics Corp., of Malvern, Pa.,received a $630,000 Phase II Small Business InnovationResearch grant from the National Institutes of Health fordevelopment of a DNA-based diagnostic test for Rhblood group incompatibility.
* Genzyme Corp., of Cambridge, Mass., raised another$19.2 million to bring the total of its Oct. 13, 1995,public offering to $147.3 million and 2.9 million sharessold. The additional funds were generated through thesale of 375,000 shares to underwriters exercising optionsto cover overallotments. CS First Boston, Cowen & Co.,Lehman Brothers and PaineWebber Inc., all of NewYork, managed the offering.
* The Upjohn Co., of Kalamazoo, Mich., approved arestructuring of its generic drug agreement with GensiaInc., of San Diego, which will receive $50 million fromthe pharmaceutical company as part of the deal.
(c) 1997 American Health Consultants. All rights reserved.